Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13218812 | 1.00 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL13218794 | 1.00 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL13052974 | 0.78 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL1053969 | 0.72 | TSHR (0.55) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL4260014 | 0.70 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL28239409 | 0.70 | ADRA2A (0.44) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL13052903 | 0.68 | — | — | |
| SCHEMBL10487817 | 0.67 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL1004977 | 0.67 | TSHR (0.46) | ADRA2AADRA2BADRA2CADRA1AADRA1B | |
| SCHEMBL196657 | 0.66 | TSHR (0.50) | ADRA2AADRA2BADRA2CADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203144-A1 | Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals | ALLERGAN, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203144-A1 | Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals | KDR, MTNR1B, VEGFA | ADRA2A 82/4885ADRA2B 18/4885ADRA2C 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.